Opinion on Pharmaceutical Manufacturers

Published within

« | ... | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Sanofi-Aventis: Acomplia chances gaining weight

The latest set of trial data concerning the use of Acomplia (rimonabant) to reduce cardiovascular risk caused by obesity has shown that the Sanofi-Aventis [SNY] drug could be used over an extended period to maintain weight loss. However, concerns over the product's side effect profile may yet dent Sanofi's hopes of rapid approval.

Published By Datamonitor
11 Nov 2004
Expert View
Expert View

Promising Antegren data ruffles Serono

Newly-released Phase III trial data for Biogen-IDEC/Elan's multiple sclerosis pipeline drug Antegren was a key issue at Serono's recent investor's meeting, giving the company an opportunity to raise concerns over the paucity of the presented data. Indeed, without supplying further details over the safety and efficacy of the drug, Biogen may struggle to gain approval in the near future.

Published By Datamonitor
12 Nov 2004
Expert View
Expert View

Tigecycline offers new hope in the battle against MRSA

Study data presented at a major recent conference has demonstrated that Wyeth's novel antibacterial tigecycline acts against drug-resistant pathogens in some serious bacterial infections, including MRSA. While Wyeth will have to work hard to establish tigecycline in this competitive area, its encouraging tolerability profile could give it a useful advantage over existing treatments.

Published By Datamonitor
12 Nov 2004
Expert View
Expert View

Sorafenib offers hope in the battle for liver cancer survival

The outlook for hepatocellular carcinoma (HCC) sufferers is bleak - current medication has a five-year survival rate for those with liver cancer of less than 5% in the developed world and even lower in developing countries. However, patients in trials of a new drug called Sorafenib have seen their survival times double. Datamonitor's Dr Lorna Fern investigates...

Published By Datamonitor
19 Nov 2004
Expert View
Expert View

Arava: the 'sixth drug' that may soon be under fire

At a recent hearing into the Vioxx affair, the FDA's Dr David Graham named five drugs that he considers too dangerous to be on the market. However, in his testimony, Dr Graham also cited Sanofi-Aventis's Arava as a drug he has recommended be withdrawn. Unlike the other five drugs, Arava has largely escaped the media spotlight, but there may yet be some tough questions asked about its safety.

Published By Datamonitor
29 Nov 2004
CommentWire
CommentWire

Novartis: Glivec provides more impressive results

Patients with chronic myeloid leukemia (CML) receiving 800mg of Glivec are more likely to attain complete cytogenetic response compared to the standard dose of 400mg. If these preliminary results translate into improved survival for CML patients then this will undoubtedly secure further revenue for Novartis [NVS] as physicians switch to high dose Glivec.

Published By Datamonitor
07 Dec 2004
Expert View
Expert View

Glaxo takes the flak for a global issue

Past criticism surrounding the price of its antiretroviral drugs in the developing world has led to GSK voluntarily licensing some of its best-selling drugs to companies in countries worst affected by the HIV/AIDS epidemic. However, as Brigitte de Lima explains, for all it will achieve, GSK's contribution is near negligible without a concerted global effort to address the problem.

Published By Datamonitor
09 Dec 2004
CommentWire
CommentWire

Pharmaceutical marketing: eHealth could take the strain

Merck & Co has increased the number of jobs it will cut by the end of 2004 from 4,400 to 5,100. The announcement comes three months after the withdrawal of its blockbuster painkiller, Vioxx. With much of the pharma industry looking to tighten its belt, eHealth solutions could offer a useful means of maintaining sales and marketing momentum.

Published By Datamonitor
15 Dec 2004
Expert View
Expert View

Pfizer's Celebrex may increase cardiovascular risk

Pfizer has announced that one of two long term cancer studies, Adenoma Prevention with Celecoxib (APC), has shown that patients receiving 400mg and 800mg of Celebrex (celecoxib) have a 2.5 fold increased risk of cardiovascular events compared to placebo. However, a similar trial, Prevention of Spontaneous Adenomatopus (PreSAP) revealed no greater cardiovascular risk than placebo.

Published By Datamonitor
20 Dec 2004
CommentWire
CommentWire

Merck & Co: OTC Mevacor remains remote prospect

Concerns about patient safety led the FDA advisory committee to vote against recommending OTC availability of Merck's [MRK] statin Mevacor. However, the FDA has until the end of February to make its final decision. The statin simvastatin has been available OTC in the UK since July 2004 under pharmacist supervision, yet such a move in the US still seems unlikely.

Published By Datamonitor
18 Jan 2005

« | ... | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | ... | » »|

No help is available.